Syndax Pharmaceuticals, based in Waltham, Massachusetts, develops cancer therapies and went public on March 3, 2016. Key products include revumenib for leukemia and axatilimab for chronic graft-versus-host disease.
Keith Katkin bought 10,000 shares of SNDX on 19 May at $9.11 per share, worth a total of $91K. They now own 100,000 SNDX shares, or a 11% holding increase.
📡️ Health Care
Insider Trades
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
